Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation
Table 3
Patient characteristics in groups with and without PT.
PT
Without PT
value
N
32
362
Patient age, median (range)
36 (3–54)
26 (2–58)
0.020
Patient sex, male, n (%)
17 (53.1)
214 (59.1)
0.320
Diagnosis, n (%)
0.510
AML
13 (40.6)
147 (40.6)
ALL
14 (43.8)
119 (32.9)
CML
1 (3.1)
21 (5.8)
MDS
3 (9.4)
38 (10.5)
Others
1 (3.1)
37 (10.2)
Disease risk, n (%)
SR
22 (68.8)
279 (77.1)
0.288
HR
10 (31.3)
83 (22.9)
HLA incompatibility, n (%)
0.533
0 locus
0
3 (0.8)
1 locus
2 (6.3)
20 (5.5)
2 loci
4 (12.5)
83 (22.9)
3 loci
26 (81.3)
256 (70.7)
Donor-patient relation, n (%)
0.260
Sibling donor
9 (28.1)
108 (29.8)
Father donor
4 (12.5)
53 (14.6)
Mother donor
9 (28.1)
141 (39.0)
Children donor
9 (28.1)
49 (13.5)
Others
1 (3.1)
11 (3.0)
Donor-patient sex match, number (%)
0.722
Male to male
11 (34.4)
138 (38.1)
Male to female
11 (34.4)
91 (25.1)
Female to male
6 (18.8)
78 (21.5)
Female to female
4 (12.5)
55 (15.2)
ABO matched, n (%)
0.213
Matched
15 (46.9)
209 (57.7)
Major mismatched
8 (25.0)
66 (18.2)
Minor mismatched
5 (15.6)
69 (19.1)
Bidirect mismatched
4 (12.5)
18 (5.0)
Cell compositions in allografts, n (%)
Infused nuclear cells ≥ median
15 (46.9)
181 (50.0)
0.735
Infused CD34+ cells ≥ median
11 (34.4)
187 (51.7)
0.061
Infused lymphocytes ≥ median
13 (48.1)
160 (50.3)
0.829
Infused CD3+ cells ≥ median
14 (51.9)
160 (50.3)
0.878
Infused CD4+ cells ≥ median
16 (59.3)
159 (50.0)
0.356
Infused CD8+ cells ≥ median
16 (59.3)
157 (49.4)
0.324
Infused CD14+ cells ≥ median
16 (59.3)
157 (49.4)
0.324
Grade II–IV aGVHD
12 (44.4)
105 (33.0)
0.229
cGVHD
8 (25.0)
120 (33.2)
0.320
HLA antibody positive
12 (37.5)
87 (24.0)
0.092
HLA-I antibody positive
6 (18.8)
57 (17.9)
0.579
HLA-II antibody positive
8 (25.0)
49 (13.5)
0.056
HLA-DP antibody positive
3 (9.4)
29 (8.0)
0.732
DSA positive
6 (18.8)
39 (10.8)
0.174
MFI > 1000
6 (18.6)
31 (8.6)
0.058
MFI > 2000
4 (12.5)
27 (7.5)
0.310
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; SR: standard risk; HR: high risk; aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease; HLA-I/II: class I/II HLA antibody; HLA-DP: class I and II HLA antibody double positive; DSA: donor-specific antibody; DSA-DP: class I and II DSA double positive; MFI: median fluorescent intensity.Bold means variates included in the multivariate analysis since their value < 0.1 in the univariate analysis.
